Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPISTAR 1-01
2024-511074-80-01Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of TUB-040 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (3 cohorts), sponsored by Gilead Sciences. Primary endpoints: Incidence of dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
TUB-040
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2024-511074-80-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511074-80-01.